Varenicline
Varenicline has been studied in 38 papers since 2014: 7 trials and 12 observational studies in people, 2 in animals, 16 reviews; 30 in the past year. It is an approved medicine. The newest paper, Nov 13, 2026: “Medication-Wide Discovery of Candidate Medications Associated with Alzheimer’s Disease and Related Dementias Using Explainable Artificial Intelligence and Longitudinal Real-World Data”.
9 new papers in 30 daysSee all 42 papers on varenicline
At a glance
A human preprint associates varenicline with lower risks of Alzheimer’s disease and related dementias, and of these dementias or death, versus nicotine replacement therapy during smoking cessation. A review describes improved combustible tobacco abstinence.
29 findings in 18 papers from 2018 to 2026, 10 of them since April 2026
Independent labs found the same change in mice and people. 12 independent labs in 10 countries; 168 trials, none about aging, 41 with no results posted.
“Individuals with the ST profile responded better to varenicline than to NRT.”
None of its findings points the other way.
- 12 independent labs in 10 countries
- 168 trials, none about aging, 41 with no results posted
- Funders: The University of Hong Kong and others
- 2 of 24 findings with company ties
- 59 of 168 trials sponsored by its developers
- Human trial7
- Humans12
- Animals2
Studies in people
1 study gave varenicline to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
up: Improves smoking abstinence35% Absolute Risk Difference (ARD) favoring varenicline over NRT (absolute cessation rates: 47% and 11%, respectively) | Randomized trialTwelve weeks | 158 people18-75 yearsGeneral population; Sign-trackers (ST) | Addiction (Abingdon, England), Feb 20, 2026 |
What did studies of varenicline find?
13Studies of varenicline measured 13 outcomes; the most studied are smoking cessation (4 studies) and cognitive function (2).
Smoking cessation
upin humans3upin reviews1OR 1.88
4 studies
Smoking cessation
upin humans3upin reviews1OR 1.88
Varenicline is linked with higher smoking cessation in humans (OR = 1.88, 95%CI 1.19-2.98).
“varenicline (OR = 1.88, 95%CI 1.19-2.98), or heated tobacco products (OR = 2.33, 95%CI 1.01-5.35) had significantly higher odds of quitting successfully”
Humansn = 5,593
PLOS mental health
Varenicline improves smoking cessation in type 2 diabetes.
“varenicline is the only medication that can be strongly recommended”
Reviewin type 2 diabetes
Diabetes research and clinical practice
Varenicline improves smoking cessation in humans (women who smoke).
“prioritize varenicline for women who smoke due to its proven superior efficacy in women.”
Reviewwomen who smokefemales
Smoking cessation in women: taking action with the Capability Approach
La Presse Médicale Formation
Varenicline improves smoking cessation (first-line pharmacotherapy).
“Varenicline and combination nicotine replacement therapy continue to demonstrate the highest efficacy among first-line agents.”
Reviewfirst-line pharmacotherapy
Emerging and Established Pharmacotherapies for Smoking Cessation: A Review
Cardiology in review
Cognitive function
upin mice2
2 studies
Cognitive function
upin mice2
Varenicline improves cognitive function in aged mice subjected to laparotomy.
“After chronic varenicline administration (1 mg/kg/day), cognitive dysfunction, hippocampal oxidative stress, as well as fragile mitophagy were improved.”
Animalsin aged mice subjected to laparotomychronic administrationbrain1 mg/kg/daymales
Varenicline improved laparotomy-induced cognitive impairment by restoring mitophagy in aged mice
European journal of pharmacology
Varenicline improves cognitive function in mice after laparotomy.
“Perioperative varenicline attenuated the cognitive decline and associated tau protein mislocalization”
Animalsafter laparotomy1 mg/kg/dayperioperativemales
Neuropharmacology
Medication adherence
no changein humans1
1 study
Medication adherence
no changein humans1
Varenicline was not clearly linked with medication adherence in humans (Compared with brand-name varenicline).
“Medication adherence declined over time in both groups and was comparable throughout follow-up (all P > 0.05).”
HumansCompared with brand-name vareniclinegeneric24 weeks
Drug and alcohol dependence
Biochemically validated 7-day point prevalence abstinence
no changein humans1
1 study
Biochemically validated 7-day point prevalence abstinence
no changein humans1
Varenicline was not clearly linked with biochemically validated 7-day point prevalence abstinence in humans (Compared with brand-name varenicline after matching) (33.2% vs. 33.2% after matching; 33.2% vs. 33.8% before matching).
“At 24 weeks, validated abstinence rates were similar between generic and brand-name varenicline both before matching (33.2% vs. 33.8%) and after matching (33.2% vs. 33.2%).”
HumansCompared with brand-name varenicline after matchinggeneric24 weeksn = 512
Drug and alcohol dependence
Tobacco abstinence
upin humans1
1 study
Tobacco abstinence
upin humans1
Varenicline improves tobacco abstinence in humans (for combustible tobacco cessation).
“varenicline recommended over monotherapy with other agents”
Reviewfor combustible tobacco cessation
Annals of internal medicine
Smoking abstinence
upin humans1
1 study
Smoking abstinence
upin humans1
Varenicline improves smoking abstinence in humans (Sign-trackers (ST)) (35% Absolute Risk Difference (ARD) favoring varenicline over NRT (absolute cessation rates: 47% and 11%, respectively)).
“Individuals with the ST profile responded better to varenicline than to NRT.”
Human trialSign-trackers (ST)Twelve weeksn = 158
Addiction (Abingdon, England)
Long-term smoking abstinence
upin humans1
1 study
Long-term smoking abstinence
upin humans1
Varenicline increases long-term smoking abstinence in humans (severe mental illness; compared with placebo or minimal care) (10 more per 100 achieving long-term smoking abstinence, 95% CI 5 to 16).
“Varenicline, bupropion, and nicotine replacement therapy likely improved smoking abstinence in people with severe mental illness compared with placebo or minimal care”
Reviewsevere mental illness; compared with placebo or minimal care
Smoking cessation for people with severe mental illness: systematic review and network meta-analysis
BMJ medicine
Smoking behavior
downin humans1
1 study
Smoking behavior
downin humans1
Varenicline decreases smoking behavior in humans.
“Other studies highlighted the significant impact of varenicline on reducing smoking behavior and urges.”
Review
Indian journal of community medicine : official publication of Indian Association of Preventive & Social Medicine
Mitophagy
upin mice1
1 study
Mitophagy
upin mice1
Varenicline improves mitophagy in aged mice subjected to laparotomy.
“After chronic varenicline administration (1 mg/kg/day), cognitive dysfunction, hippocampal oxidative stress, as well as fragile mitophagy were improved.”
Animalsin aged mice subjected to laparotomychronic administrationhippocampus1 mg/kg/daymales
Varenicline improved laparotomy-induced cognitive impairment by restoring mitophagy in aged mice
European journal of pharmacology
Oxidative stress and ROS signaling
downin mice1
1 study
Oxidative stress and ROS signaling
downin mice1
Varenicline decreases oxidative stress and ROS signaling in aged mice subjected to laparotomy.
“After chronic varenicline administration (1 mg/kg/day), cognitive dysfunction, hippocampal oxidative stress, as well as fragile mitophagy were improved.”
Animalsin aged mice subjected to laparotomychronic administrationhippocampus1 mg/kg/daymales
Varenicline improved laparotomy-induced cognitive impairment by restoring mitophagy in aged mice
European journal of pharmacology
All 13Fewer
What is varenicline linked with?
9Studies link varenicline with 9 measures, among them major adverse cardiovascular events, Alzheimer's disease and related dementias and Alzheimer's disease and related dementias risk.
Major adverse cardiovascular events
downin humans2HR 0.57
2 studies
Major adverse cardiovascular events
downin humans2HR 0.57
Varenicline is associated with major adverse cardiovascular events in humans (Nicotine or tobacco dependence; compared with no varenicline use) (HR 0.57; 95% CI 0.55-0.59).
“varenicline was associated with lower risk of MACE (HR 0.57; 95% CI 0.55-0.59)”
HumansNicotine or tobacco dependence; compared with no varenicline use3 yearsn = 128,359
Association of Major Adverse Cardiovascular Events with Varenicline versus Bupropion
AHA Scientific Sessions 2026 abstract
Varenicline is associated with major adverse cardiovascular events in humans.
“Both varenicline and bupropion individually showed lower mortality and MACE.”
HumansAfter acute coronary syndrome; added to nicotine replacement therapy versus nicotine replacement therapy alone
AHA Scientific Sessions 2026 abstract
Alzheimer's disease and related dementias
downin humans1downin silico1HR 0.516
2 studies
Alzheimer's disease and related dementias
downin humans1downin silico1HR 0.516
Varenicline is linked with a lower risk of Alzheimer's disease and related dementias in humans (receiving smoking cessation therapy relative to nicotine replacement therapy) (HR 0.516, 95% CI: 0.353-0.754).
“Varenicline use was associated with a reduced risk of ADRD (HR 0.516, 95% CI: 0.353-0.754)”
Humansreceiving smoking cessation therapy relative to nicotine replacement therapy
Varenicline as a Repurposable Drug Candidate for ADRD Prevention
medRxiv : the preprint server for health sciencesPreprint
Varenicline is associated with Alzheimer's disease and related dementias in silico.
“Our analyses yielded both suspected candidates, such as varenicline, which has supportive preclinical and early clinical evidence in ADRD, and novel candidates, such as metolazone”
In silico
Hybrid Value-Aware Transformer Identifies Novel and Suspected Drugs for Alzheimer’s Disease
GSA 2025 abstract
Alzheimer's disease and related dementias risk
downin humans1
1 study
Alzheimer's disease and related dementias risk
downin humans1
Varenicline is associated with Alzheimer's disease and related dementias risk in humans (model-derived association) (Population-level impact score −0.134 per 280 mg; negative scores in 8341 of 8786 users (95%)).
“Metolazone and varenicline had the most negative population-level impact scores: −0.196 per 1800 mg and −0.134 per 280 mg cumulative dose unit, respectively”
Humansmodel-derived association280 mg cumulative dose unitn = 8,786
Medical sciences (Basel, Switzerland)
Continuous smoking abstinence
upin humans1HR 1.09
1 study
Continuous smoking abstinence
upin humans1HR 1.09
Varenicline is associated with continuous smoking abstinence in humans (Nicotine or tobacco dependence; varenicline compared with bupropion) (HR 1.09; 95% CI 1.02-1.17).
“and other cardiovascular outcomes, as well as higher continuous abstinence rates (HR 1.09; 95% CI 1.02-1.17).”
HumansNicotine or tobacco dependence; varenicline compared with bupropion3 yearsn = 118,234
Association of Major Adverse Cardiovascular Events with Varenicline versus Bupropion
AHA Scientific Sessions 2026 abstract
Smoking cessation
upin humans1HR 2.32
1 study
Smoking cessation
upin humans1HR 2.32
Varenicline is associated with smoking cessation in humans (HR 2.32; 95% CI 2.12-2.53).
“Both therapies increased smoking cessation (varenicline HR 2.32; 95% CI 2.12-2.53; bupropion HR 2.25; 95% CI 2.06-2.45).”
HumansNicotine or tobacco dependence; compared with no varenicline use; cessation identified by ICD-10 code3 yearsn = 128,359
Association of Major Adverse Cardiovascular Events with Varenicline versus Bupropion
AHA Scientific Sessions 2026 abstract
Mortality
downin humans1
1 study
Mortality
downin humans1
Varenicline is associated with mortality in humans.
“Both varenicline and bupropion individually showed lower mortality and MACE.”
HumansAfter acute coronary syndrome; added to nicotine replacement therapy versus nicotine replacement therapy alone
AHA Scientific Sessions 2026 abstract
Nonserious adverse reactions
upin humans1
1 study
Nonserious adverse reactions
upin humans1
Varenicline is associated with nonserious adverse reactions in humans (Compared with brand-name varenicline) (32.4% vs. 12.1% at week 1; 18.0% vs. 7.0% at week 12).
“adverse reactions were more frequently reported with generic varenicline (32.4% vs. 12.1% at week 1; 18.0% vs. 7.0% at week 12; all P < 0.001)”
HumansCompared with brand-name vareniclinegenericWeeks 1 and 12
Drug and alcohol dependence
Smoking abstinence
upin humans1OR 4.46
1 study
Smoking abstinence
upin humans1OR 4.46
Varenicline is associated with smoking abstinence in humans (OR 4.46, 95% CI 1.51–13.16; p = 0.007).
“varenicline (OR = 4.46, 95% CI 1.51–13.16, p = 0.007) significantly increased the likelihood of smoking abstinence compared to NRT”
HumansCompared with nicotine replacement therapy; adjusted for cardiovascular disease history, pack-years, and nicotine dependence12 weeks58% malessn = 169
ESC Congress 2026 abstract
ADRD or death
downin humans1HR 0.657
1 study
ADRD or death
downin humans1HR 0.657
Varenicline is linked with a lower risk of ADRD or death in humans (receiving smoking cessation therapy relative to nicotine replacement therapy) (HR 0.657, 95% CI: 0.501-0.861).
“and the composite outcome ADRD or death (HR 0.657, 95% CI: 0.501-0.861).”
Humansreceiving smoking cessation therapy relative to nicotine replacement therapy
Varenicline as a Repurposable Drug Candidate for ADRD Prevention
medRxiv : the preprint server for health sciencesPreprint
What acts on varenicline?
1Studies name nicotine replacement therapy as acting on varenicline.
Nicotine replacement therapy
no changein humans1OR 1.06
1 study
Nicotine replacement therapy
no changein humans1OR 1.06
Nicotine replacement therapy showed no clear effect on varenicline in network meta-analysis (OR 1.06, 95% CrI 0.75-1.48).
“combination nicotine replacement therapy showed no clear difference versus varenicline in network meta-analysis (odds ratio, 1.06; 95% credible interval, 0.75-1.48)”
Reviewin network meta-analysis
Korean journal of family medicine
Has varenicline been tested in people?
0 of 168 about agingYes: 7 trials and 12 observational studies in people have been published, and 159 trials are registered.
Latest change Dry eye disease: Human trials → ApprovedNov 11, 2026
Approved
May 10, 2006Smoking Cessation
Sep 25, 2006Tobacco Use Cessation, Smoking Cessation
Oct 15, 2021Dry Eye Disease
Repurposing
Phase 4Completed3 trials
Phase 4Results posted1 trial
Phase 4Terminated5 trials
Chronic obstructive pulmonary disease
Phase 4Completed2 trials
Phase 3Completed1 trial
Phase 4Results posted2 trials
40 of 53Fewer
In trials
Cigarette smoking
Phase 4Results posted11 trials
Vaping
Phase 4Recruiting5 trials
Alcohol drinking
Phase 4Results posted4 trials
Cognition disorder
Phase 4Results posted2 trials
Marijuana Abuse
Phase 4Recruiting2 trials
Attention deficit disorder with hyperactivity
Phase 4Terminated1 trial
All 10Fewer
Readouts due
- Dec 7, 2026
Switching to E-cigarettes in Smokers Not Interested in Quitting
Phase 3Recruiting
- Aug 31, 2027
Evaluating Smoking Cessation Interventions for PWH in South Africa
Phase 2/3Recruiting
Stopped
NCT00907218TerminatedSmoking cessation
extremely slow enrollment
NCT01772641TerminatedTobacco use disorder
difficulty recruiting and retaining participants
NCT04602494TerminatedTobacco use disorder
The pilot study used apo-varenicline under temp FDA authorization. When varenicline was available an IND exemption was granted to enroll children, IRB approved a trial of varenicline in participants ages 16-25 June 27, 2022, the pilot was terminated
NCT02147132TerminatedSmoking
Difficulty recruiting eligible participants; study medication was expiring.
NCT02473562TerminatedParkinson's disease
insufficient patient enrollment, insufficient funds for completion
NCT02856581TerminatedLung neoplasm
Slow accrual
All 9Fewer
Who is developing varenicline?
1 company: Kriya Therapeutics.
- Companies
- Kriya TherapeuticsPhase 1/2trigeminal neuralgia
Trial sponsors
Company25 trialsPhase 415,647 people
Company2 trialsPhase 451 people
Company2 trialsPhase 3349 people
Company1 trialPhase 1/224 people
Company1 trialPhase 122 people
Medical University of South Carolina
10 trialsPhase 41,847 people
10 trialsPhase 41,103 people
7 trialsPhase 4165 people
Funding
5 grants since 2018National Institute of Neurological Disorders and Stroke$2.2MNational Cancer Institute$1.2MUS Department of Veterans Affairs
Varenicline for Smoking Reduction in Veterans Unwilling to Quit
US Department of Veterans AffairsWm S. Middleton Memorial Veterans Hosp2026–2030
Reducing falls with Varenicline in Hypocholinergic Parkinson disease
National Institute of Neurological Disorders and StrokeUniversity of Michigan at Ann Arbor$1.1M2024–2030
National Cancer InstituteUniversity of Oklahoma Hlth Sciences Ctr$607K2025–2029
Reducing falls with Varenicline in Hypocholinergic Parkinson disease
National Institute of Neurological Disorders and StrokeUniversity of Michigan at Ann Arbor$1.2M2024–2026
Behavioral Activation and Varenicline for Smoking Cessation in Depressed Smokers
National Cancer InstituteNorthwestern University$596K2014–2020
How this record changed
Summary written from the findings.